Institutional members access full text with Ovid®

Share this article on:

Analgesic tolerance induced by repeated morphine injections induces cross-tolerance to the analgesic effect of orexin-A in rats

Azhdari-Zarmehri, Hassana,*; Ghasemi, Elmirab,*; Heidari-Oranjaghi, Nimac; Sadegh, Mehdid

doi: 10.1097/WNR.0000000000000964
Cellular, Molecular and Developmental Neuroscience

Repeated administration of morphine or orexin-A produces tolerance to their antinociceptive effects. We investigated the possible incidence of cross-tolerance between orexin-A and morphine. Adult male Sprague-Dawley rats (200–250 g) were used. Under deep anesthesia, a stereotaxic apparatus was used to implant a 23 G cannula into the lateral ventricle for an intracerebroventricular (ICV) microinjection. The antinociceptive effect of three different doses of orexin-A (5, 20, and 40 µM; dissolved in 5 µl sterile saline; ICV) was examined using the hot-plate test at 15, 30, 60, and 90 min after infusion. To evaluate tolerance, orexin-A (20 µM; ICV) or morphine (10 mg/kg; intraperitoneal) was administered for 7 consecutive days (twice per day) and the analgesic response was assessed at days 1, 4, and 7. Cross-tolerance was investigated at day 8 with a single injection of morphine (10 mg/kg; intraperitoneal) to the repeated orexin-A group and a single microinjection of orexin-A (20 µM; ICV) to the repeated morphine group. Analgesic responses were then examined. Administration of both orexin-A and morphine produced significant antinociception at day 1 (P<0.001 compared with the saline group). However, a significant reduction in the analgesic effects of both morphine and orexin-A appeared at day 7, following repeated administration (P<0.01). Orexin-A microinjection at day 8 in the repeated morphine group did not result in significant antinociception (P>0.05), whereas morphine injection in the repeated orexin-A group at day 8 showed a significant analgesic effect (P<0.001). These results indicate cross-tolerance to the analgesic effect of orexin-A following morphine tolerance.

aDepartment of Basic Sciences and Neuroscience Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh

bCellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar

cDepartment of Physiology, Zanjan University of Medical Sciences, Zanjan

dDepartment of Physiology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran

* Hassan Azhdari-Zarmehri and Elmira Ghasemi contributed equally to the writing of this article.

Correspondence to Mehdi Sadegh, PhD, Department of Physiology, Faculty of Medicine, Arak University of Medical Sciences, Arak 3848176941, Iran Tel: +98 863 417 3502; fax: +98 863 417 3521; e-mail: m.sadegh@arakmu.ac.ir

Received November 14, 2017

Accepted December 7, 2017

© 2018 Wolters Kluwer Health | Lippincott Williams & Wilkins